{
    "relation": [
        [
            "",
            "Number of Participants Analyzed [units: participants]",
            "Number of Events of First Discontinuation of FPV/RTV or LPV/RTV Alone Due to the Indicated Adverse Events [units: events]",
            "Hypersensitivity reaction",
            "GI Tract",
            "Pancreas",
            "Nervous system",
            "Kidneys",
            "Other side effects (not specified as above)"
        ],
        [
            "All Participants",
            "167",
            "",
            "1",
            "5",
            "1",
            "2",
            "1",
            "3"
        ]
    ],
    "pageTitle": "Fosamprenavir in Pts With Hepatic Impairment - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01054586?sect=Xj015&view=results",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989234.2/warc/CC-MAIN-20150728002309-00082-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 848284267,
    "recordOffset": 848273644,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Participant Flow: \u00a0 Overall Study Lopinavir (LPV), Standard Dose LPV, Standard Dose All other dosages of FPV (excluding FPV 700 mg BID/RTV 100 mg BID and FPV 700 mg BID/RTV 100 mg QD) FPV, Other FPV 700 mg BID/RTV 100 mg once a day (QD) FPV 700 mg BID/RTV 100 mg QD Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID FPV 700 mg BID/RTV 100 mg BID Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details As this was an observational, retrospective study, no participants were recruited for participation in this study. For more information about this study, see the protocol in ClinicalTrials.gov and/or search for this study (111949) on http://www.gsk-clinicalstudyregister.com/. Key information relevant to the recruitment process for the",
    "textAfterTable": "\u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered. Reporting Groups \u00a0 Description FPV 700 mg BID/RTV 100 mg BID Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID FPV 700 mg BID/RTV 100 mg QD FPV 700 mg BID/RTV 100 mg once a day (QD) FPV, Other All other dosages of Fosamprenavir LPV, Standard Dose Lopinavir (LPV), Standard Dose Total Total of all reporting groups Baseline Measures",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}